Profound Medical Corp (PROF)

Profound Medical's stock has experienced fluctuations over the past six months. PRO FAMILIA Specialist Hospital in Poland completed its 500th Sonalleve procedure, followed by a stock price decrease. The company announced its participation in investor events, also followed by a stock price decrease. Mount Sinai Hospital became the first in the New York Metro Area to offer the TULSA Procedure, followed by a stock price increase. Profound announced it surpassed its 2025 TULSA-PRO installed base goal, followed by a stock price increase. Johns Hopkins Medicine treated its first commercial TULSA-PRO case, followed by a stock price decrease. Profound Medical completed a registered direct offering and a private placement to fund sales and marketing expansion, working capital, R&D, and strategic transactions. Profound Medical reported its Q3 2025 earnings, with revenues rising 87% to $5.3 million compared to Q3 2024.

Information regarding specific demand seasonality for Profound Medical Corp.'s products and services was not explicitly found. The nature of medical device sales may suggest a relatively consistent demand driven by disease prevalence and treatment needs rather than strong seasonal fluctuations.

Profound Medical Corp. is a Canadian medical technology company specializing in minimally invasive therapeutic solutions. Their primary product is the TULSA-PRO system for prostate conditions, which combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control. They also commercialize Sonalleve, a therapeutic platform for uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical Corp. is headquartered in Mississauga, Ontario, Canada, and has a network of clinical partners and distributors across North America and Europe. Its Sonalleve devices are operational in parts of Europe, China, and Southeast Asia. The company markets its incision-free therapeutic systems in Canada, Germany, the United States, and Finland.

Profound Medical has maintained a reputation as an innovative medical technology company focused on incision-free therapies. Clinical and commercial milestones, such as the successful completion of Sonalleve procedures and the expansion of TULSA-PRO into major medical centers, have positively impacted the company's brand. However, the company has faced challenges with limited revenue growth and unprofitability since TULSA-PRO's FDA approval, leading to investor concerns and a "Hold" consensus rating from analysts.

Profound Medical Corp. has 47 institutional owners and shareholders holding a total of 12,059,346 shares, representing 39.08% of the shares outstanding. The largest individual shareholder is Arun Swarup Menawat, the CEO, who owns 587,089 shares, representing 1.94% of the company.